XOMA Corporation Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Subsequent Events (Details)

Subsequent Events (Details)							1 Months Ended	12 Months Ended
Subsequent Events (Details)	Mar. 04, 2024 shares	Feb. 16, 2024 Right payment $ / shares	Jan. 11, 2024 USD ($)	Jan. 09, 2024 shares	Jan. 07, 2024 USD ($)	Jun. 21, 2023 USD ($)	Jan. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jan. 02, 2024 USD ($)
Subsequent Event
Payments of consideration under RPAs, AAAs and CPPAs								$ 14,650,000	$ 8,000,000
Contingent consideration under RPAs, AAAs and CPPAs								7,000,000	$ 75,000
Assignment and Assumption Agreement and Royalty Purchase Agreement \| LadRx
Subsequent Event
Payments of consideration under RPAs, AAAs and CPPAs						$ 5,000,000.0
Assignment and Assumption Agreement and Royalty Purchase Agreement \| LadRx \| Regulatory milestones
Subsequent Event
Contingent consideration under RPAs, AAAs and CPPAs						$ 1,000,000.0		$ 1,000,000.0
Subsequent Event
Subsequent Event
Stock repurchase program amount authorized										$ 50,000,000.0
Number of shares repurchased \| shares	660
Subsequent Event \| Kinnate
Subsequent Event
Acquiree's common stock, par value (in dollars per share) \| $ / shares		$ 0.0001
Base price per share (in dollars per share) \| $ / shares		2.3352
Additional cash price per share (in dollars per share) \| $ / shares		$ 0.2527
Number of non-transferable contingent value rights for each acquiree share \| Right		1
Percentage of net proceeds from disposition entered into by acquiree prior to expiration of offer acquiree has right to receive		100.00%
Percentage of net proceeds payable from disposition entered into by entity after expiration of offer acquiree has right to receive		85.00%
Subsequent Event \| Kinnate \| Minimum
Subsequent Event
Cash amount of consideration per outstanding share (in dollars per share) \| $ / shares		$ 2.3352
Number of cash payments for each contingent value right \| payment		1
Subsequent Event \| Kinnate \| Maximum
Subsequent Event
Cash amount of consideration per outstanding share (in dollars per share) \| $ / shares		$ 2.5879
Subsequent Event \| Alora Pharmaceuticals \| Talphera
Subsequent Event
Maximum eligible milestone payments receivable							$ 116,500,000
Subsequent Event \| Alora Pharmaceuticals \| Talphera \| All customers excluding DoD
Subsequent Event
Royalties entity has right to receive (as a percent)							15.00%
Subsequent Event \| Alora Pharmaceuticals \| Talphera \| DoD
Subsequent Event
Royalties entity has right to receive (as a percent)							75.00%
Subsequent Event \| Acquisition of economic interest agreement \| Talphera
Subsequent Event
Threshold amount for royalties and milestones							$ 20,000,000.0
Subsequent Event \| Acquisition of economic interest agreement \| Talphera
Subsequent Event
Payments of consideration under RPAs, AAAs and CPPAs							$ 8,000,000.0
Royalties and milestones entity has the right to receive (as a percent)							100.00%
Maximum remaining milestones to be shared equally							$ 116,500,000
Subsequent Event \| Acquisition of economic interest agreement \| Talphera \| All customers excluding DoD
Subsequent Event
Royalties entity has right to receive (as a percent)							15.00%
Subsequent Event \| Acquisition of economic interest agreement \| Talphera \| DoD
Subsequent Event
Royalties shared equally with counterparty (as a percent)							75.00%
Subsequent Event \| Assignment and Assumption Agreement and Royalty Purchase Agreement \| LadRx
Subsequent Event
Payments of consideration under RPAs, AAAs and CPPAs			$ 1,000,000.0
Subsequent Event \| CEO, Owen Hughes
Subsequent Event
Amount of annual base salary					$ 575,000
Target annual cash bonus (as a percent)					60.00%
Subsequent Event \| CEO, Owen Hughes \| Performance share units
Subsequent Event
Number of shares granted \| shares				275,000